Filing Analysis
Caribou Biosciences, Inc. filed an 8-K to furnish its quarterly financial results for the period ended June 30, 2026, and provided a general business update via press release.
📋 Key Facts
- Report date: August 13, 2026
- Reporting period: Quarter ended June 30, 2026
- The filing includes an earnings press release as Exhibit 99.1
- Company is classified as an emerging growth company
Caribou Biosciences reported the results of its 2026 Annual Meeting of Stockholders held on June 17, 2026. While directors were elected and the auditor was ratified, a proposal to expand officer exculpation in the company's certificate of incorporation was not approved.
🚩 Red Flags
- Stockholders rejected the proposal to provide officers with expanded exculpation from fiduciary duty breaches, indicating potential shareholder dissatisfaction with corporate governance or officer accountability.
📋 Key Facts
- Election of three Class II Directors (Andrew Guggenhime, David Johnson, and Nancy Whiting) was successful.
- Deloitte & Touche LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- Proposal 3, regarding the exculpation of officers from certain breaches of fiduciary duty, failed to pass.
- Proposal 4, allowing for the adjournment of the meeting to solicit more votes for Proposal 3, was approved, but the company ultimately decided not to adjourn.
Caribou Biosciences announced positive long-term follow-up data from two phase 1 clinical trials: the ANTLER trial for vispa-cel (anti-CD19) in B-NHL and the CaMMouflage trial for CB-011 (anti-BCMA) in multiple myeloma. The company is moving toward a pivotal phase 3 trial for vispa-cel and expects further dose expansion data for CB-011 in H2 2026.
🚩 Red Flags
- Reported two deaths related or possibly related to vispa-cel in the pivotal subgroup (N=27).
- Reported one death related to CB-011 in the dose escalation portion (N=48).
📋 Key Facts
- Vispa-cel (ANTLER trial) showed an 82% overall response rate (ORR) and 67% complete response rate in a pivotal subgroup of 27 second-line LBCL patients.
- Vispa-cel demonstrated a median progression-free survival (PFS) of 17.1 months.
- CB-011 (CaMMouflage trial) showed a 92% ORR and 83% complete response or stringent complete response rate in 12 BCMA-naïve patients.
- CB-011 achieved 91% MRD negativity in 10 of 11 evaluable patients.
- The company has aligned with the FDA on the design of the ANTLER-3 phase 3 trial, targeting ~250 patients.
- Vispa-cel safety: One vispa-cel-related death due to IEC-HS and one possibly related death due to PML in the pivotal subgroup.
- CB-011 safety: One CB-011-related death due to immune effector cell-associated hematotoxicity across 48 patients.
Caribou Biosciences announced its financial results for the first quarter ended March 31, 2026, and provided a general business update. The disclosure was made via a press release furnished as an exhibit to the filing.
📋 Key Facts
- Announced financial results for the quarter ended March 31, 2026
- Provided a business update in the accompanying press release (Exhibit 99.1)
- The report was filed under Item 2.02 (Results of Operations and Financial Condition)
- The filing was signed by President and CEO Rachel E. Haurwitz, Ph.D.
Caribou Biosciences announced that the FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to CB-011, its allogeneic anti-BCMA CAR-T cell therapy for relapsed or refractory multiple myeloma. The candidate is currently being evaluated in the ongoing CaMMouflage Phase 1 clinical trial.
📋 Key Facts
- FDA granted RMAT designation for CB-011 on March 31, 2026.
- CB-011 is an allogeneic anti-BCMA CAR-T cell therapy product candidate.
- The designation is for the treatment of relapsed or refractory multiple myeloma (r/r MM).
- CB-011 is currently in the CaMMouflage Phase 1 clinical trial.
Caribou Biosciences announced its financial results for the fourth quarter and fiscal year ended December 31, 2025. The filing includes a press release providing a business update alongside the financial data.
📋 Key Facts
- Reported financial results for Q4 2025 and the full year ended December 31, 2025
- Filing date of March 5, 2026
- The information was furnished under Item 2.02 and is not deemed 'filed' for liability purposes
- Includes Exhibit 99.1: Press Release Issued by Caribou Biosciences, Inc. on March 5, 2026
Caribou Biosciences, Inc. has filed an 8-K to furnish its quarterly financial results for the period ended September 30, 2025, and a related business update via press release.
📋 Key Facts
- Report date: November 12, 2025
- Reporting period: Quarter ended September 30, 2025
- The filing includes an earnings press release (Exhibit 99.1) and a business update.
- Company is classified as an emerging growth company.
Caribou Biosciences announced preliminary Q3 2025 financial results, reporting approximately $159.2 million in cash and marketable securities. The company also released significant clinical data from its ANTLER phase 1 trial for vispa-cel and dose escalation data for CB-011.
🚩 Red Flags
- Reported one instance of a Grade 5 adverse event (IEC-HS) related to vispa-cel.
- 28% of patients in the optimized cohort experienced prolonged cytopenias.
📋 Key Facts
- Preliminary cash, cash equivalents, and marketable securities as of Sept 30, 2025: ~$159.2 million.
- ANTLER phase 1 trial (vispa-cel) confirmatory cohort (N=22): 82% ORR, 64% CR rate, and 51% 12-month PFS.
- Optimized product profile cohort (N=35): 86% ORR, 63% CR rate, and 53% 12-month PFS.
- FDA has recommended a randomized, controlled pivotal phase 3 trial for vispa-cel in 2L LBCL CD19-naïve patients.
- One reported vispa-cel-related grade 5 IEC-HS event occurred on day 25 post-infusion.
Caribou Biosciences, Inc. filed an 8-K to furnish its quarterly financial results for the period ended June 30, 2025, and provided a general business update via press release.
📋 Key Facts
- Reporting date: August 12, 2025
- Period covered: Quarter ended June 30, 2025
- The filing includes results of operations and financial condition updates.
- Company is an emerging growth company.
Caribou Biosciences has received formal notice from Nasdaq confirming it has regained compliance with the minimum $1.00 bid price requirement. The company met this requirement by maintaining a closing bid price of $1.00 or greater between June 3, 2025, and June 17, 2025.
🚩 Red Flags
- Historical non-compliance with Nasdaq minimum bid price requirement indicates past extreme volatility or downward pressure on stock price.
📋 Key Facts
- Received written notice from Nasdaq Staff on June 18, 2025.
- Regained compliance with Nasdaq Listing Rule 5450(a)(1) (minimum $1.00 bid price).
- Compliance period noted: June 3, 2025, to June 17, 2025.
Caribou Biosciences held its 2025 Annual Meeting of Stockholders on June 12, 2025. The most significant outcome was the stockholder approval of an amendment to effect a reverse stock split at a ratio between 1-for-5 and 1-for-50.
🚩 Red Flags
- Approval of a reverse stock split (ratio up to 1-for-50) is often used to regain compliance with minimum bid price requirements for NASDAQ listing or to improve share perception, which can be viewed as a sign of distress in micro-cap/biotech stocks.
📋 Key Facts
- Annual Meeting held on June 12, 2025.
- Stockholders approved a reverse stock split with a ratio between 1-for-5 and 1-for-50, as determined by the Board of Directors.
- Two Class I directors (Scott Braunstein, M.D. and Ran Zheng, M.S.) were elected to terms ending in 2028.
- Deloitte & Touche LLP was ratified as the independent registered public accounting firm for fiscal year 2025.
- The meeting reached a quorum; adjournment was not necessary.
Caribou Biosciences, Inc. filed an 8-K to furnish its quarterly financial results for the period ended March 31, 2025, and provided a general business update via press release.
📋 Key Facts
- Report date: May 8, 2025
- Reporting period: Quarter ended March 31, 2025
- The filing includes results of operations and financial condition updates under Item 2.02
- Company is an emerging growth company
Caribou Biosciences is implementing a strategic restructuring involving significant workforce reductions and the discontinuation of several clinical programs to prioritize its lead oncology candidates. The company aims to extend its cash runway into the second half of 2027 through these cost-reduction measures.
🚩 Red Flags
- Significant workforce reduction (32% of staff) indicates aggressive cost-cutting to preserve capital.
- Discontinuation of clinical programs and preclinical research suggests a narrowing focus due to resource constraints.
- High burn rate implied by the need for substantial restructuring to reach 2027 runway.
📋 Key Facts
- Workforce reduction of 47 employees, representing approximately 32% of the total workforce.
- Discontinuation of the GALLOP phase 1 clinical trial (CB-010 in lupus) and AMpLify phase 1 clinical trial (CB-012 for AML).
- Estimated restructuring costs between $2.5 million and $3.5 million, including $1.8M–$2.0M for severance.
- Preliminary cash position of $212.5 million in cash, equivalents, and marketable securities as of March 31, 2025.
- Projected cash runway extending into the second half of 2027 based on current operating plans.
- Planned presentation of CB-010 (ANTLER trial) and CB-011 (CaMMouflage trial) data in the second half of 2025.
Caribou Biosciences, Inc. filed an 8-K to furnish its fourth quarter and full year 2024 financial results and a business update via press release.
📋 Key Facts
- Reporting period: Fourth quarter and fiscal year ended December 31, 2024.
- Filing date: March 10, 2025.
- The filing includes Exhibit 99.1 containing the press release with financial results and business updates.
Caribou Biosciences issued a press release under Item 7.01 to highlight its 2024 corporate accomplishments and provide an outlook for anticipated clinical milestones in 2025.
🚩 Red Flags
- Forward-looking statements regarding clinical data results carry inherent risks that actual outcomes may differ materially.
📋 Key Facts
- Company plans to present ANTLER phase 1 clinical trial data (second-line and prior CD19 relapsed large B cell lymphoma) in H1 2025.
- Anticipated commencement of ANTLER pivotal phase 3 clinical trial is expected in 2025.
- Dose escalation data from the CaMMouflage phase 1 trial (CB-011) for multiple myeloma is expected in H1 2025.
- Updates on dose escalation from the AMpLify Phase 1 trial (CB-012) are anticipated.
- Updates from the GALLOP phase 1 trial (CB-010) for lupus nephritis and extrarenal lupus are anticipated.
Caribou Biosciences, Inc. announced the appointment of Sriram Ryali as Chief Financial Officer (CFO), effective January 2, 2025. This appointment concludes the interim designation of Ryan Fischesser in the roles of principal financial officer and principal accounting officer.
📋 Key Facts
- Sriram Ryali appointed CFO, Principal Financial Officer, and Principal Accounting Officer effective Jan 2, 2025.
- Ryali's compensation includes a $485,000 annual base salary and a target discretionary bonus of 40% of base salary.
- Equity component: Stock option to purchase 300,000 shares with a one-year cliff (25% vesting after 12 months).
- Ryali previously served as CFO at Codexis, Inc. and Eiger BioPharmaceuticals, Inc.
- Ryan Fischesser's interim designations as principal financial/accounting officer terminated upon Ryali's start date.
Caribou Biosciences, Inc. issued an 8-K to furnish its quarterly financial results for the period ended September 30, 2024, and provided a general business update via press release.
📋 Key Facts
- Report date: November 6, 2024
- Reporting period: Quarter ended September 30, 2024
- The filing includes a press release (Exhibit 99.1) containing financial results and business updates.
- Company is an emerging growth company.
Caribou Biosciences, Inc. filed an amendment to its 8-K to provide additional details regarding the resignation of CFO Jason O’Byrne and the appointment of Ryan Fischesser as interim Principal Financial Officer and Principal Accounting Officer.
🚩 Red Flags
- Sudden departure of the Chief Financial Officer (CFO) can sometimes signal internal friction or financial reporting concerns, though not explicitly stated here.
- Use of an 'interim' officer suggests a transition period that may delay long-term strategic financial planning.
📋 Key Facts
- Jason O'Byrne resigned as Chief Financial Officer, effective September 27, 2024.
- Ryan Fischesser (current VP of Finance and Controller) appointed as interim Principal Financial Officer and interim Principal Accounting Officer, effective September 27, 2024.
- Mr. Fischesser will be granted 25,000 Restricted Stock Units (RSUs) on November 20, 2024, vesting in full on November 20, 2025.
- The appointment is intended to last until a new permanent CFO is appointed.
Caribou Biosciences announced the resignation of its CFO, Jason O’Byrne, effective September 27, 2024. The company will appoint current VP of Finance and Controller Ryan Fischesser as the interim principal accounting officer.
🚩 Red Flags
- C-suite turnover (CFO) can create transitional friction and administrative overhead during critical clinical/development phases for biotech companies.
📋 Key Facts
- CFO Jason O’Byrne to resign effective September 27, 2024, to pursue another opportunity.
- Resignation is not due to any disagreement regarding financial reporting or accounting policies/procedures.
- Ryan Fischesser (current VP of Finance and Controller) will assume the role of principal accounting officer on September 27, 2024.
- Fischesser previously served as principal accounting officer from IPO through December 15, 2022.
Caribou Biosciences, Inc. announced the appointment of Tina Albertson as the company's new Chief Medical Officer on August 12, 2024.
📋 Key Facts
- Appointment of Tina Albertson as Chief Medical Officer (CMO).
- Announcement date: August 12, 2024.
- The announcement was made via press release under Items 7.01 and 8.01.
Caribou Biosciences, Inc. issued an 8-K to announce its financial results for the quarter ended June 30, 2024, and provided a business update via press release.
📋 Key Facts
- Report date: August 6, 2024
- Reporting period: Quarter ended June 30, 2024
- The filing includes an announcement of financial results and a business update (Exhibit 99.1).
Caribou Biosciences is discontinuing its allogeneic CAR-NK platform research and reducing its workforce by approximately 12% (21 positions) to extend its cash runway. The company aims to focus resources on its allogeneic CAR-T cell therapy platform and four clinical programs.
🚩 Red Flags
- Significant workforce reduction (12%) often indicates a pivot or financial tightening.
- Discontinuation of an entire research platform (CAR-NK) suggests a narrowing of strategic scope and potential loss of R&D sunk costs.
📋 Key Facts
- Discontinuation of preclinical research activities for the allogeneic CAR-NK platform.
- Workforce reduction of 21 positions, representing approximately 12% of the workforce.
- Estimated cash runway extension: at least six months into the second half of 2026.
- Preliminary unaudited cash, cash equivalents, and marketable securities: $311.8 million as of June 30, 2024.
- Estimated restructuring costs: $0.5 million to $1.0 million to be recognized in Q3 2024.
Caribou Biosciences, Inc. held its annual meeting of stockholders on June 13, 2024. The filing reports the election of three Class III directors and the ratification of Deloitte & Touche LLP as the independent registered public accounting firm.
📋 Key Facts
- Annual Meeting held on June 13, 2024.
- Election of Rachel Haurwitz, Ph.D., Dara Richardson-Heron, M.D., and Natalie Sacks, M.D. to the Board as Class III directors (terms until 2027).
- Ratification of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year ending December 31, 2024.
- Proposal 2 received 73,021,434 votes in favor.
Caribou Biosciences issued an 8-K to announce updated clinical data from its ongoing ANTLER Phase 1 trial for CB-010, an allogeneic anti-CD19 CAR-T cell therapy. The company hosted a webcast and presented findings at the ASCO Annual Meeting.
📋 Key Facts
- Announced updated clinical data for CB-010 (allogeneic/off-the-shelf anti-CD19 CAR-T cell therapy) from the ANTLER Phase 1 trial.
- The trial is evaluating patients with relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL).
- Data presentation included a summary of initial dose expansion results.
- Clinical results were presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting on June 3, 2024.
Caribou Biosciences, Inc. filed an 8-K to furnish its quarterly financial results for the period ended March 31, 2024, and provided a general business update via press release.
📋 Key Facts
- Report date: May 7, 2024
- Reporting period: Quarter ended March 31, 2024
- The filing includes an earnings press release as Exhibit 99.1
- Company is classified as an 'emerging growth company'
Caribou Biosciences announced FDA clearance of its Investigational New Drug (IND) application for CB-010, an allogeneic anti-CD19 CAR-T cell therapy. This marks a strategic expansion into treating autoimmune diseases, specifically lupus nephritis and extrarenal lupus.
🚩 Red Flags
- Forward-looking statements regarding the sufficiency of cash to fund current operating plans (standard cautionary language, but noted).
📋 Key Facts
- FDA cleared the IND application for CB-010 to treat lupus nephritis (LN) and extrarenal lupus (ERL).
- The company plans to initiate the phase 1, multicenter, open-label GALLOP clinical trial by year-end 2024.
- This represents a strategic pivot/expansion from oncology into autoimmune disease indications.
- Patients in both the GALLOP and ANTLER trials will be screened for donor-specific antibodies to optimize manufacturing matching.
Caribou Biosciences, Inc. issued an 8-K to furnish its fourth quarter and full year 2023 financial results and a business update via press release.
📋 Key Facts
- Report covers the fourth quarter and fiscal year ended December 31, 2023.
- The filing includes an earnings press release as Exhibit 99.1.
- Company is classified as an 'Emerging Growth Company'.
- Filing date: March 11, 2024.
Caribou Biosciences announced the appointment of Tim Kelly as the company's new Chief Technology Officer on January 7, 2024. The filing also highlights corporate accomplishments from 2023 and provides an outlook for clinical milestones in 2024.
📋 Key Facts
- Appointment of Tim Kelly as Chief Technology Officer (CTO).
- Company provided updates on 2023 clinical events and corporate achievements.
- Management outlined anticipated 2024 clinical milestones for product candidates CB-010, CB-011, and CB-012.